Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes.
Optimal implementation of adoptive T-cell therapy for cancer will likely require multiple and maintained genetic modifications of the infused T cells and their progeny so that they home to tumor sites and recognize tumor cells, overcome tumor immune evasion strategies, and remain safe. Retroviral vectors readily transduce T cells and integrate into the host cell genome, but have a limited capacity for multigene insertion and cotransduction and are prohibitively expensive to produce at clinical grade. Genetic modification of T cells using transposons as integrating plasmids is an attractive alternative because of the increased simplicity and cost of production. Of available transposons, piggyBac has the higher transposase activity and larger cargo capacity, and we now evaluate piggyBac for potential adoptive therapies with primary T cells. PiggyBac transposons mediated stable gene expression in approximately 20% of primary T cells without selection. Treatment and maintenance of T cells with interleukin-15 increased stable transgene expression up to approximately 40% and expression was sustained through multiple logs of expansion for over 9 weeks in culture. We demonstrate simultaneous integration of 2 independent transposons in 20% of T cells, a frequency that could be increased to over 85% by selection of a transgenic surface marker (truncated CD19). PiggyBac could also deliver transposons of up to 13 kb with 10,000-fold expansion of transduced T cells in culture and finally we demonstrate delivery of a functional suicide gene (iCasp9). PiggyBac transposons may thus be used to express the multiple integrated transgenes that will likely be necessary for the broader success of T-cell therapy.
Nakazawa
Yozo
Y
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
Huye
Leslie E
LE
Dotti
Gianpietro
G
Foster
Aaron E
AE
Vera
Juan F
JF
Manuri
Pallavi R
PR
June
Carl H
CH
Rooney
Cliona M
CM
Wilson
Matthew H
MH
D017209:Apoptosis; D019496:Cancer Vaccines; D053453:Caspase 9 / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D002478:Cells, Cultured; D004251:DNA Transposable Elements / Q000276:immunology*; D005818:Genetic Engineering; D005822:Genetic Vectors; D006801:Humans; D016219:Immunotherapy, Adoptive; D019409:Interleukin-15 / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000378:metabolism*; D019076:Transgenes / Q000235:genetics
D019496:Cancer Vaccines; D004251:DNA Transposable Elements; D019409:Interleukin-15; C506433:CASP9 protein, human; D053453:Caspase 9